Jonathan Rubin, SVP and Chief Medical Officer of Supernus Pharmaceuticals, Inc., filed a Form 4 on August 14, 2026, disclosing transactions in common stock dated August 12, 2026, related to the vesting of Performance Share Units.

Key Highlights

  • PSU vesting: 750 Performance Share Units vested on August 12, 2026, converting to 750 shares of common stock at a price of $0.
  • Tax withholding: 363 shares were withheld by the company to satisfy tax withholding requirements, at a price of $46.57 per share.
  • Resulting ownership: Following the reported transactions, Rubin directly holds 13,979 shares of common stock.
  • PSU award origin: The Performance Share Units were originally awarded on February 19, 2025, with performance objectives established on May 3, 2025.
  • ESPP shares: The pre-transaction total of 14,342 shares included 251 shares acquired through the company's Employee Stock Purchase Plan.

Supernus Pharmaceuticals CMO Jonathan Rubin: PSU Vesting Details

According to the filing, Jonathan Rubin, serving as SVP and Chief Medical Officer at Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), reported two transactions in common stock on August 12, 2026. The first was coded "M," reflecting the acquisition of 750 shares at $0 through the vesting of Performance Share Units. The filing notes that these PSUs were awarded on February 19, 2025, and that a portion vested "upon the achievement of individual performance objectives within a defined performance period," with those objectives established on May 3, 2025.

The second transaction, coded "F," involved the disposition of 363 shares at $46.57 per share. According to the filing, this represents "the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units." Following these two transactions, the filing reports Rubin's direct beneficial ownership at 13,979 shares of common stock.

The filing also notes that the pre-transaction figure of 14,342 shares included an aggregate of 251 shares acquired through the issuer's Employee Stock Purchase Plan. All transactions are reported as direct ownership. The Form 4 was signed by Timothy C. Dec as attorney-in-fact and filed on August 14, 2026.

What Was Disclosed

The filing discloses the vesting of 750 Performance Share Units and the withholding of 363 shares for taxes by Supernus Pharmaceuticals, resulting in direct beneficial ownership of 13,979 shares of common stock for CMO Jonathan Rubin as of August 12, 2026.